Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021Julia W. Gargano, Sara E. Oliver, Veronica V. McNally et al.|MMWR Morbidity and Mortality Weekly Report|2021Cited by 602
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021Hannah G. Rosenblum, Sara E. Oliver, Stephen C. Hadler et al.|MMWR Morbidity and Mortality Weekly Report|2021Cited by 215
Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022Hannah G. Rosenblum, Evelyn Twentyman, Megan J. Wallace et al.|MMWR Morbidity and Mortality Weekly Report|2022Cited by 163
Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023Joanna J. Regan, Megan Wallace, Danielle Moulia et al.|MMWR Morbidity and Mortality Weekly Report|2023Cited by 142
Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health SystemChristopher Warren, Kari C. Nadeau, Theo T. Snow et al.|JAMA Network Open|2021Cited by 137